



Get Clarity On Generics

Cost-Effective CT & MRI Contrast Agents



FRESENIUS
KABI

WATCH VIDEO

AJNR

This information is current as
of August 11, 2025.

Pictorial Review of Glutamate Excitotoxicity: Fundamental Concepts for Neuroimaging

Leighton P. Mark, Robert W. Prost, John L. Ulmer,
Michelle M. Smith, David L. Daniels, James M.
Strodtmann, W. Douglas Brown and Lotfi Hachein-Bey

AJNR Am J Neuroradiol 2001, 22 (10) 1813-1824
<http://www.ajnr.org/content/22/10/1813>

Pictorial Review of Glutamate Excitotoxicity: Fundamental Concepts for Neuroimaging

Leighton P. Mark, Robert W. Prost, John L. Ulmer, Michelle M. Smith, David L. Daniels, James M. Strottmann, W. Douglas Brown, and Lotfi Hachein-Bey

Neuroradiologists may encounter, on a daily basis, a challenging diversity of neurologic disorders, including stroke, trauma, epilepsy, and even neurodegenerative conditions, such as Huntington disease, AIDS dementia complex, and amyotrophic lateral sclerosis (1), but this spectrum of disease is not usually thought of as sharing the same mechanism of neuronal injury and death. These and a growing list of other neurologic disorders are now understood to share a final common destructive metabolic pathway called excitotoxicity (2, 3), which has been the focus of intense investigative efforts in the neurosciences over the past several decades (3–31). Excitotoxicity refers to an excessive activation of neuronal amino acid receptors. The specific type of excitotoxicity triggered by the amino acid glutamate is the key mechanism implicated in the mediation of neuronal death in many disorders. The discovery of excitotoxic injury is a major clue in the search for answers to such fundamental questions as why neurons die in disease states and what is the precise or critical mechanism of neuronal death.

This overview introduces and reviews some of the major concepts of glutamate excitotoxicity. Familiarity with this intriguing pathologic process will enhance the understanding of the neuroimaging changes of many neuropathologic processes, facilitate a conceptual model for some of the newer treatment strategies for some disorders (ie, stroke and trauma), and perhaps cultivate new directions for neuroimaging. The organization of this article follows the excitotoxic process from the formation of glutamate to neuronal death.

Glutamate excitotoxicity is a broad and rapidly evolving field of study with many important nuances that have necessarily been oversimplified or, unfortunately, omitted from this review for the sake of reasonable brevity. The reader is referred to the exponentially expanding literature and some of the

sources listed in the reference section for additional information.

Glutamate

Glutamate is an amino acid and one of a group of amino acid neurotransmitters in the brain, although it is the principal excitatory neurotransmitter. More basically, amino acids (Fig 1) consist of a central carbon atom (α carbon) bonded to a carboxyl group (COOH) and an amino group (NH₂). A distinctive side chain (R group), which characterizes each amino acid, links to the α carbon. Glutamate (Fig 2) consists of the side chain CH₂CH₂COO⁻ (COOH ending [γ carboxyl group] for glutamic acid) attached to the α carbon, while the closely related glutamine (Fig 3A and B) is created from glutamate with ammonia added at the γ carboxyl group by glutamine synthetase, forming the CH₂CH₂CONH₂ side chain R group. Cerebral glutamate is derived solely from endogenous sources; mainly from α ketoglutarate, which is a product of the Krebs cycle (citric acid cycle, TCA [tricarboxylic acid] cycle).

The neuronal glutamate considered here acts as a neurotransmitter, which is the method of communication between neurons. This interaction between neurons may be either excitatory or inhibitory. The major excitatory amino acid neurotransmitters are glutamate and aspartate, while GABA (γ -aminobutyric acid), glycine (aminoacetic acid), and taurine are inhibitory.

The processing and transport of glutamate (Fig 4) within the neuron are highly organized and coordinated interactions among multiple cytoplasmic organelles resembling the frenetically detailed but choreographed mosaic activities of an ant farm (32). Glutamate, like other neurosecretory substances, is initially synthesized by the endoplasmic reticulum and then transported to the Golgi apparatus for additional processing. Emerging from the opposite surface of the Golgi apparatus and wrapped inside a vesicular (bilipid) membrane, glutamate is then transported down the axon via a complex system of microtubules. Antegrade motion down the axon on the microtubules is mediated by molecules called motor kinesin, whereas cytoplasmic dynein generates retrograde motion. Mitochondria also accompany these transport molecules, providing the required energy. Upon reaching the

Received March 26, 2001; accepted after revision June 14.

From the Neuroradiology Section, Department of Diagnostic Radiology, Medical College of Wisconsin, Froedtert Hospital, 9200 W Wisconsin Ave, Milwaukee, WI 53226. Address reprint requests to Leighton P. Mark, MD.

Presented in part at the annual meeting of the American Society of Neuroradiology, San Diego, May 1999.

© American Society of Neuroradiology





FIG 1. Amino acid. Typical amino acid consists of a central alpha carbon (C_α) that is bonded to a carboxyl group (COOH) on one side and an amino group (H_3N) on the other side. Each amino acid is characterized by a distinctive molecular group (R) or side chain attached to the α carbon.

FIG 2. Glutamate. The side chain, or R group, of glutamic acid is $\text{CH}_2\text{CH}_2\text{COOH}$. The carboxyl group of the side chain is designated the γ carboxyl group, which becomes fully ionized at neutral pH and is therefore frequently written with a negative charge (COO^-). The term glutamate (instead of glutamic acid) is used to indicate this negative charge or ionized state at physiological pH.

FIG 3. A, Glutamine. This closely related amino acid is formed from glutamate with the addition of an amino group at the γ carboxyl of the side chain.

B, This formation of an amide linkage at the γ carboxyl group requires the enzyme glutamine synthetase and the process is adenosine triphosphate (ATP)-dependent. This reaction is also a major mechanism for the detoxification of cerebral ammonia.



axonal tip (Fig 5), the vesicle with the enclosed glutamate merges with the presynaptic membrane by the process called exocytosis to release the glutamate into the synaptic space between neurons. The vesicular membrane is then recycled and transported back up the neuronal axon in a retrograde fashion via the microtubular network. The synaptic glutamate is finally freed to interact with specific receptor sites on the postsynaptic membrane of the adjacent neuron to initiate an important cascade of molecular events within that neuron (Fig 6).

Postsynaptic Anatomy

The interaction of glutamate with the postsynaptic membrane requires a review of glutamate receptors (Fig 7). The two main types of glutamate receptors are ionotropic and metabotropic. Ionotropic receptors are directly coupled to membrane ion channels. The metabotropic receptors are coupled to intermediary compounds, such as G protein, and modulate intracellular second messengers, such as inositol-1,4,5-trisphosphate (IP_3), calcium, and cyclic nucleotides. The directly coupled ionotropic




FIG 4. Neuronal glutamate processing and transport. Glutamate is processed by the endoplasmic reticulum and Golgi apparatus in preparation for fast axonal transport, which also requires other transport proteins and mitochondria. When glutamate emerges from the "trans" face of the Golgi apparatus, it is encapsulated inside a neurosecretory vesicle, which consists of a bilipid membrane. These vesicles are transported down the axon along microtubule tracks to be deposited at the tip of the axon near the presynaptic membrane. Waves of axonal membrane depolarization would trigger the release of the glutamate into the synaptic space by exocytosis, which is exhibited by the merging of the neurosecretory vesicles with the postsynaptic membrane to free the packaged glutamate. The empty vesicle would then be recycled back to the neuronal body by retrograde transport along the microtubular tracks (adapted from [32]).

receptor, which is the primary consideration of this review, can be further subdivided into three subtypes: NMDA (*N*-methyl-D-aspartate), AMPA (*α*-amino-3-hydroxy-5-methyl-4-isoxazolepropionate), and kainate. These subtypes are named for their selective chemical agonists, which resemble glutamate but do not naturally exist in the brain. This nomenclature may seem awkward, but it offers the convenience and consistency of grouping the various cerebral and cerebellar receptors according to their responses to the chemical tools that are used to evaluate or stimulate them.

Excessive accumulation of intracellular calcium is the key observed process leading to neuronal death or injury, and the NMDA receptors activate channels that allow the influx of extracellular calcium (and sodium). Overstimulation of this type of glutamate receptor would then lead to neuronal calcium overload. Some types of AMPA and kainate receptors can contribute to intracellular calcium overload because their coupled membrane ion channels are at least partially permeable to calcium.

The influx of calcium and sodium from glutamate receptor stimulation results in membrane depolarization, which can also activate voltage-dependent calcium channels. These other calcium channels then allow further calcium influx, aggra-




FIG 5. A–C, Electron micrographs show neurosecretory vesicles releasing neurotransmitter molecules by exocytosis on the presynaptic membrane. Numerous small neurotransmitter substances can be seen in the synaptic space (open arrows). These neurotransmitters will then settle on and activate receptors on the postsynaptic membrane. Dark circles by straight solid arrows represent vesicles filled with neurotransmitters. Light partial circles by curved solid arrows represent the vesicle merging with the presynaptic membrane and releasing neurotransmitter into the synaptic space (adapted from [32]).

vating the intracellular calcium overload initiated by overstimulation of the glutamate receptors and opening of the associated ion channels. The four main types of voltage-dependent calcium channels considered here are named for their specific properties: T (transient current), N (found in neurons), L (long duration current, large conductance channels), and P (found in Purkinje cells of the cerebellum). The L channel is not the most prevalent type but it disproportionately contributes to calcium-mediated neuronal injury because of the prolonged calcium influx that occurs with activation of this voltage-dependent conduit.

Multiple modulatory sites, however, complicate some of the ionotropic receptors. It may be helpful to think of the receptors as a receptor-channel complex with the receptor closely linked to and controlling the adjacent ion channel. Modulatory sites are separate areas on the receptor and the channel in which other molecules can influence the function of the receptor site or channel. On the NMDA receptors, glycine (once considered a laboratory con-




FIG 6. Pictorial display of the neurotransmitter glutamate (orange) released into the synaptic space and docking with the glutamate receptor site on the postsynaptic membrane. The activation of the glutamate receptor then opens the ion channel coupled to the receptor, allowing the passage of extracellular calcium (yellow) into the intracellular cytosol, which in turn triggers a series of biochemical events (adapted from Schornak S, *BNI Q* 11:1995)




FIG 7. Ionotropic and metabotropic receptors. The ionotropic receptors NMDA (purple) and AMPA (red) are directly coupled to ion channels. The metabotropic receptors (blue and orange) activate intermediary molecules such as G protein affecting multiple cytoplasmic enzymes to produce molecules, such as IP_3 , that increase cytosol calcium concentrations. Also depicted are modulatory substances, such as spermine, which facilitate calcium influx, and receptor complex inhibitors, such as zinc, magnesium, and PCP. L-2-amino-4-phosphonopropionic acid (L-AP4) and aminocyclopentyl dicarboxylic acid (ACPD) receptors are classified as metabotropic, as they are coupled to intermediary G proteins (G) that activate phosphodiesterase (PDE) for L-AP4 receptors and form inositol 1,4,5-trisphosphate (IP_3) and diacylglycerol (DAG) from phosphatidylinositol 4,5-bisphosphate (PIP_2) for the ACPD receptors via phospholipase C. 2-amino-3-phosphonopropionic acid (AP3) and quinoxaline-2,3-dione (NBQX) are antagonists for ACPD and AMPA receptors, respectively.

taminant) acts as a required coagonist. Hydrogen ions (a reflection of pH) suppress receptor activation. Polyamines, such as spermine, however, can relieve proton block and potentiate NMDA receptor activation in a pH-dependent fashion. The NMDA receptor channels are affected by multiple factors, including magnesium (which blocks the channel), zinc (positive and negative modulator), and multiple drugs, such as dizocilpine and phencyclidine (PCP, "angel dust") channel blocker (Fig 8).

Calcium

Glutamate excitotoxic calcium overload can be appreciated from the perspective of the normal mechanisms of neuronal calcium homeostasis. Intracellular cytosolic free calcium is maintained at very low concentrations (micromolar) relative to free extracellular calcium. Plasma membrane calcium transporters regulate this cytosolic free calcium concentration. Membrane transporters in general have been classified as antiporters, symporters, and ATP-coupled active transporters (Fig 9). These transporters are membrane protein compounds that are coupled to energy sources and change the distribution of substrate ions or molecules across a membrane. Antiporters and symporters are called secondary




FIG 8. Schematic representation of NMDA, AMPA, and kainate receptors as receptor-channel complexes. Glutamate docks with the receptor, which opens the coupled channel to allow the intracellular influx of extracellular calcium. Other molecules (such as magnesium, zinc, and PCP) can influence receptor function by interacting with several receptor and channel modulatory sites.

transporters because they use the energy from an existing ion gradient to drive the passage of another ion or molecule in the same (symporter) or opposite (antiporter) direction across a membrane as the energizing ion. Movement through the neuronal mem-




FIG 9. Membrane channels and transporters. The ion channels are pathways to allow the diffusion of ions across the cell membrane. These channels can be opened or closed by changes in membrane voltage, associated ligands, and so on. Excessive intracellular calcium is detrimental to neuronal health, and a calcium gradient is maintained across the neuronal membrane mostly by three main types of transporters. The antiporters use an existing ion gradient (usually established by active or ATP-dependent transport) to transport calcium ions (green) in the opposite direction of the energizing ion (ie, sodium). Symporters transport calcium in the same direction of the energizing ion (blue). Both antiporter and symporters are considered secondary transporters because they derive energy from an existing gradient. The ATP-coupled active transporter is considered a primary transporter that uses ATP to affect the transmembrane movement of calcium to establish its gradient (adapted from [32]).

brane is achieved by a change in the conformation of the protein-substrate complex. Complexing with two or more substrates is required to initiate conformational transitions in antiporters (opposite direction coupling) and symporters (same direction coupling). The primary transporters (ATP-coupled active transporter) couple a chemical reaction to the protein conformational transitions that supply the metabolic energy required to generate concentration gradients of substrate ions across the membrane. Calcium is controlled by the antiporter and plasma-membrane calcium pump (PMCA). The antiporter, which has a low affinity but high transport capacity for calcium, moves calcium out of the neuron by a sodium-calcium exchange mechanism. The sodium gradient across the membrane drives this exchanger. The PMCA, on the other hand, has a high affinity




FIG 10. Calcium homeostasis. Membrane transporter (antiporter and ATP-dependent transporter) maintain a much higher extracellular calcium (small circles) concentration than the cytosol. The endoplasmic reticulum and mitochondria are important sources of intracellular extracytosolic calcium. These internal sources of calcium can be released into the cytosol when provoked by specific agents, such as the second messenger (IP_3) actions on the endoplasmic reticulum (adapted from [32]).

but low transport capacity for calcium. This active pump transports one Ca^{2+} for each ATP hydrolyzed. One distinguishing feature of the PMCA is the enhanced activation of the pump by binding Ca^{2+} /calmodulin, which results in a 20- to 30-fold increase in the affinity of the substrate Ca^{2+} site (33).

The mitochondrion and endoplasmic reticulum are also significant sources of calcium stores. An antiporter mechanism maintains high calcium concentrations in the mitochondria by moving free calcium from the cytosol to the mitochondria while an antiporter and an ATP-dependent active pump sequester the endoplasmic reticulum calcium (Fig 10).

Glutamate receptor overstimulation increases intracellular calcium by directly opening ion channels and secondarily affecting calcium homeostatic mechanisms. As mentioned, the initial glutamate receptor opening of the sodium/calcium channels not only allows the influx of calcium but also causes membrane depolarization. The depolarization would in turn activate the voltage-dependent calcium channels, which would further increase the intracellular calcium levels. The decreased sodium gradient across the cell membrane caused by the glutamate receptor-coupled channels, however, would also reduce the ability of the sodium gradient-dependent antiporter to remove intracellular calcium. Superimposed disorders that decrease ATP production (ie, hypoxia, neurodegenerative disorders, etc) would adversely affect the activity of the ATP-dependent calcium transporters as well as the energy-dependent sodium potassium pump,





FIG 11. Excessive accumulation of intracellular calcium caused by overactivation of the glutamate receptor sites stimulates multiple enzymes, which are involved in normal neuronal development and function, resulting in damage to the cell membrane, cytoskeleton, and DNA.

FIG 12. Abnormally increased activation of some enzymes, such as phospholipase A, can cause an intracellular feedback cycle of events, leading to cell death.



which would then also affect the transmembrane sodium gradient and therefore the antiporter function.

Intracellular Toxic Events

The accumulation of high intracellular calcium levels triggers a cascade of membrane, cytoplasmic, and nuclear events leading to neurotoxicity. Elevation of the intracellular calcium, however, appears to be a complex issue, because inducing similar intracellular calcium levels by using a metabolic inhibitor such as cyanide or membrane depolarization with potassium causes less permanent neuronal damage than with glutamate. The glutamate-induced elevated calcium levels proceed to overactivate a number of enzymes, including protein kinase C, calcium/cadmodulin-dependent protein kinase II, phospholipases, proteases, phosphatases, nitric oxide synthase, endonucleases, and ornithine decarboxylase (Fig 11). Some of these enzymes can also produce positive feedback loops to accelerate the downward spiral toward neuronal death (Fig 12). Activation of phospholipase A, for example, would generate platelet-activating factor and arachidonic acid and its metabolites. Platelet-activating factor directly contributes to the excitotoxic cascade by increasing glutamate release. Arachidonic acid inhibits reuptake of glutamate from the synaptic space, leading to further activation of glutamate receptors and more arachidonic acid formation. Increased arachidonic acid levels form oxygen free radicals, which

activate phospholipase A, leading to more arachidonic acid formation. These enzymes and the generated feedback loops rapidly lead to neuronal self-digestion by protein breakdown, free radical formation, and lipid peroxidation.

Another important activated enzyme is nitric oxide synthase, which forms nitric oxide. Nitric oxide performs a variety of normal biological functions but the excessively stimulated NMDA receptors will produce abnormally increased levels of nitric oxide and superoxide ions. These substances may react and form peroxynitrite, which is extremely toxic, resulting in neuronal death. Nitric oxide can damage DNA as well as inhibit mitochondrial respiration, which in turn would create more free radicals and cause additional membrane depolarization. The nitric oxide-initiated neurotoxic cascades are important components of the mechanism of cell death in many neurodegenerative disorders, including Huntington disease (34–54).

Excessive Glutamate Accumulation

The key process that triggers the entire excitotoxic cascade is the excessive accumulation of glutamate in the synaptic space. This can be achieved by altering the normal cycling of intracranial glutamate (Fig 13) to increase the release of glutamate into the extracellular space or to decrease glutamate uptake/transport from the synaptic space, or by frank spillage of glutamate from injured neurons.





FIG 13. Neuronal glutamate that is released into the synaptic space is normally removed from the synaptic space by adjacent glial cells, in which the glutamate is converted to the closely related glutamine, which can then readily diffuse back into the neuron. Glutamine is converted back to glutamate in the neuron.

FIG 14. Diagram shows sequence of events occurring in cerebral ischemia leading to neuronal death. (Free radical formation and lipase activation are also related to the increased intracellular calcium, although the two processes are not directly connected to the increased calcium by arrows in this schematic.)





FIG 15. MR spectrum of a normal frontal lobe obtained at 1.5 T with a single-voxel point-resolved spectroscopy (PRESS) technique at 1500/41 (TR/TE).

FIG 16. MR spectrum of the same frontal lobe as in Figure 15 obtained at 0.5 T with a single-voxel PRESS technique at 1500/41. Note the more conspicuous glx peak.

Trauma is a blunt mechanism that massively elevates the extracellular glutamate levels. Normal extracellular glutamate concentration is about 0.6 $\mu\text{mol/L}$. Substantial neuronal excitotoxic injury occurs with glutamate concentrations of 2 to 5 $\mu\text{mol/L}$. Traumatic injury to neurons can produce disastrous results with the exposure of the normal intracellular glutamate concentrations of about 10 $\mu\text{mol/L}$ to the extracellular space. Mechanical in-

jury to a single neuron, therefore, puts all of the neighboring neurons at risk. Significant collateral injury occurs to surrounding neurons from this type of glutamate release. One recent therapeutic strategy is to immediately treat persons with injuries to the head or spinal column with glutamate receptor blockers to minimize the spread of neuronal death beyond the immediate physically disrupted neurons.




FIG 17. A, Coronal T2-weighted MR image of a patient with right mesial temporal sclerosis.

B, MR spectrum obtained from a voxel (indicated in A) centered in the region of the patient's right hippocampal formation shows an elevated glx peak.




FIG 18. A, Proton-density-weighted MR image in a patient with MELAS shows bilateral abnormal signal intensity changes at the periphery of the occipital lobes.

B, MR spectrum obtained at 0.5 T shows elevated glx and lactate peaks from a sampling of the normal-appearing right frontal lobe of same patient (voxel placement indicated in A).

Several mechanisms of excess glutamate accumulation probably come into play in ischemia (Fig 14). Abnormal release of glutamate from its storage sites in neuronal vesicles is at least one factor. A feedback loop is generated as this released glutamate stimulates additional glutamate release. Ischemia also causes energy failure that impairs the reuptake by glutamate transporters. These transporters behave as symporters, which rely on the sodium gradient across cell mem-

branes to move glutamate against its concentration gradients into the cell. The sodium gradient, however, is maintained by an energy-dependent pump that fails in ischemia. Such failure not only affects glutamate transport out of the synaptic space but also causes the transporters to run backward, becoming a source of extracellular glutamate rather than a sink for it. Ischemia deprives the neurons of oxygen and glucose, resulting in energy failure; however, energy failure

itself is not particularly toxic to neurons. Neural toxicity occurs with the resultant activation of the cascade of glutamate receptor-dependent mechanisms. If these receptors are blocked by appropriate antagonists, the neurons can survive a period of deprivation of oxygen and metabolic substrate. This is the rationale for the recent development and trial of glutamate receptor blockers to treat acute ischemic events (55–66). While an infarcted zone cannot be salvaged, the hope is to prevent surrounding damage to the at-risk adjacent penumbra.

These receptor blockers may also be critical in the developing arena of interventional and pharmacologically related attempts to reestablish perfusion to acutely ischemic areas of the brain. Tissue reperfusion and increased oxygen concentrations to ischemic areas without concurrent halting of the excitotoxic cascade either at the receptor or intracellular levels may increase rather than decrease neuronal damage by providing additional free radicals in the form of superoxide anions as well as by increasing the intracellular cytosol calcium levels by stimulating the release of mitochondrial calcium stores.

Acceptance of the significant role of mitochondria in neuronal death and excitotoxicity is reflected in the rapidly expanding literature on this topic during the past decade (26, 49, 67–81). Preliminary investigations into the mechanisms of mitochondrial calcium homeostasis have already inspired several therapeutic neuroprotective strategies.

A number of drugs have been developed and used in an attempt to interrupt, influence, or temporarily halt the glutamate excitotoxic cascade toward neuronal injury (82–88). One strategy is the “upstream” attempt to decrease glutamate release. This category of drugs includes riluzole, lamotrigine, and lifarizine, which are sodium channel blockers. The commonly used nimodipine is a voltage-dependent channel (L-type) blocker. Attempts have also been made to affect the various sites of the coupled glutamate receptor itself. Some of these drugs include felbamate, ifenprodil, magnesium, memantine, and nitroglycerin. These “downstream” drugs attempt to influence such intracellular events as free radical formation, nitric oxide formation, proteolysis, endonuclease activity, and ICE-like protease formation (an important component in the process leading to programmed cell death, or apoptosis). Apoptosis occurs as part of the complex process of neuronal death, but many investigators believe that excitotoxicity and apoptosis are essentially different mechanisms that have intersecting influences (27, 56, 89–106).

Neuroradiologic Observations

Routine neuroimaging studies reflect the sequela of glutamate excitotoxic damage. The spreading involvement of adjacent brain tissue beyond the immediate area of insult in trauma and infarction is one example, and the delayed presentation of these

conditions is another. The insidious brain parenchymal loss noted on imaging studies in patients with AIDS dementia is also thought to be related to glutamate excitotoxic injury.

The development of spectroscopy at 0.5 T has provided an intriguing opportunity to observe the combined glutamate and glutamine (glx) peak in vivo (107). Delineation of this peak is enabled by the coalescence of the multiplets of glx at this field strength (Figs 15 and 16). The collapse of the γ and β multiplet resonances can be briefly summarized by the ratio of δ/J (δ = chemical shift, J = spin-spin coupling constant), which governs the spectral appearance of a strongly coupled multiplet structure such as glx. The spin-spin coupling constant is determined by molecular structure and is independent of field strength, whereas the chemical shift between coupled spins is a linear function of field strength. Therefore, as the ratio of δ/J approaches zero (or decreases), the multiplet collapses toward a single resonance line.

Interesting clinical observations are then possible and have been made with the ability to examine the glx peak. Glutamate excitotoxicity has been the implicated mechanism of neuronal injury in mesial temporal sclerosis with consistent, strong supportive experimental data (108–121). Elevated glx peaks have been observed in the hippocampi of these patients (Fig 17A and B) (122). Mitochondrial disorders, such as MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke), are functionally ischemic, although there is no hypoperfusion but rather an inability to utilize the available oxygen. Imaging findings may be variable, but spectroscopic sampling of apparently normal-appearing areas of the brain by routine imaging can reveal not only the expected lactate peaks but also an elevated glx peak (Fig 18A and B). Even neurodegenerative disorders, such as Huntington disease, have been evaluated by this technique, and elevated glx peaks have been observed in the basal ganglia (123–125).

Summary

Glutamate excitotoxicity is the final common pathway resulting in neuronal injury for many seemingly unrelated disorders, including ischemia, trauma, seizures, hypoglycemia, hypoxia, and even some neural degenerative disorders. Familiarity with this process is important for neuroradiologists because of its central position in many of the disorders encountered in daily practice. This area has been one of the most intensely investigated fields in the neurosciences over the past several decades, and the information generated from this work will clearly influence our basic understanding of many neurologic disorders.

References

1. Waggle KS, Kahle PJ, Tolwani RJ. Neurons and mechanisms of neuronal death in neurodegenerative diseases: a brief review. *Lab Anim Sci* 1999;49:358–362

2. Olney J. **Neurotoxicity of excitatory amino acids.** In: McGeer E, Olney J, McGeer P, eds. *Kainic Acid as a Tool in Neurobiology*. New York: Raven Press; 1978:95–121
3. Olney JW. **Role of excitotoxins in developmental neuropathology.** *APMIS Suppl* 1993;40:103–112
4. Choi D. **Glutamate neurotoxicity in cortical cell culture is calcium dependent.** *Neurosci Lett* 1985;58:293–297
5. Abele AE, Scholz KP, Scholz WK, Miller RJ. **Excitotoxicity induced by enhanced excitatory neurotransmission in cultured hippocampal pyramidal neurons.** *Neuron* 1990;4:413–419
6. Pujol R, Rebillard G, Puel JL, Lenoir M, Eybalin M, Recasens M. **Glutamate neurotoxicity in the cochlea: a possible consequence of ischaemic or anoxic conditions occurring in ageing.** *Acta Otolaryngol Suppl* 1990;476:32–36
7. Dubinsky JM, Rothman SM. **Intracellular calcium concentrations during “chemical hypoxia” and excitotoxic neuronal injury.** *J Neurosci* 1991;11:2545–2551
8. Coyle JT, Puttfarcken P. **Oxidative stress, glutamate, and neurodegenerative disorders.** *Science* 1993;262:689–695
9. Dubinsky JM. **Examination of the role of calcium in neuronal death.** *Ann N Y Acad Sci* 1993;679:34–42
10. Lombardi G, Szekely AM, Bristol LA, Guidotti A, Manev H. **Induction of ornithine decarboxylase by N-methyl-D-aspartate receptor activation is unrelated to potentiation of glutamate excitotoxicity by polyamines in cerebellar granule neurons.** *J Neurochem* 1993;60:1317–1324
11. Lipton SA, Rosenberg PA. **Excitatory amino acids as a final common pathway for neurologic disorders [see comments].** *N Engl J Med* 1994;330:613–622
12. Lipton SA. **Ca²⁺, N-methyl-D-aspartate receptors, and AIDS-related neuronal injury.** *Int Rev Neurobiol* 1994;36:1–27
13. Lukas W, Jones KA. **Cortical neurons containing calretinin are selectively resistant to calcium overload and excitotoxicity in vitro.** *Neuroscience* 1994;61:307–316
14. Orrenius S, Nicotera P. **The calcium ion and cell death.** *J Neural Trans Suppl* 1994;43:1–11
15. Redmond JM, Gillinov AM, Zehr KJ, et al. **Glutamate excitotoxicity: a mechanism of neurologic injury associated with hypothermic circulatory arrest.** *J Thorac Cardiovasc Surg* 1994;107:776–787
16. Taylor-Robinson SD, Weeks RA, Sargentoni J, et al. **Evidence for glutamate excitotoxicity in Huntington’s disease with proton magnetic resonance spectroscopy (letter).** (Published erratum appears in *Lancet* 1994;343:1580 [see comments].) *Lancet* 1994;343:1170
17. Bading H, Segal MM, Sucher NJ, Dudek H, Lipton SA, Greenberg ME. **N-methyl-D-aspartate receptors are critical for mediating the effects of glutamate on intracellular calcium concentration and immediate early gene expression in cultured hippocampal neurons.** *Neuroscience* 1995;64:653–664
18. Hoffman PL. **Glutamate receptors in alcohol withdrawal-induced neurotoxicity.** *Metab Brain Dis* 1995;10:73–79
19. Mattson MP, Barger SW, Begley JG, Mark RJ. **Calcium, free radicals, and excitotoxic neuronal death in primary cell culture.** *Methods Cell Biol* 1995;46:187–216
20. Hugon J, Vallat JM, Dumas M. **Role of glutamate and excitotoxicity in neurodegenerative diseases.** *Rev Neurol* 1996;152:239–248
21. Paschen W. **Glutamate excitotoxicity in transient global cerebral ischemia.** *Acta Neurobiol Exp* 1996;56:313–322
22. Sucher NJ, Awobuluyi M, Choi YB, Lipton SA. **NMDA receptors: from genes to channels.** *Trends Pharmacol Sci* 1996;17:348–355
23. Perez Velazquez JL, Frantseva MV, Carlen PL. **In vitro ischemia promotes glutamate-mediated free radical generation and intracellular calcium accumulation in hippocampal pyramidal neurons.** *J Neurosci* 1997;17:9085–9094
24. Shaw PJ, Ince PG. **Glutamate, excitotoxicity and amyotrophic lateral sclerosis.** *J Neurol* 1997;244(Suppl 2):S3–S14
25. Brown JI, Baker AJ, Konasiewicz SJ, Moulton RJ. **Clinical significance of CSF glutamate concentrations following severe traumatic brain injury in humans.** *J Neurotrauma* 1998;15:253–263
26. Budd SL. **Mechanisms of neuronal damage in brain hypoxia/ischemia: focus on the role of mitochondrial calcium accumulation.** *Pharmacol Ther* 1998;80:203–229
27. Lipton SA, Nicotera P. **Calcium, free radicals and excitotoxins in neuronal apoptosis.** *Cell Calcium* 1998;23:165–171
28. Rubin LL. **Neuronal cell death: an updated view.** *Prog Brain Res* 1998;117:3–8
29. Lipton SA, Nakanishi N. **Shakespeare in love—with NMDA receptors?** *Nat Med* 1999;5:270–271
30. Nicholls DG, Budd SL, Castilho RF, Ward MW. **Glutamate excitotoxicity and neuronal energy metabolism.** *Ann N Y Acad Sci* 1999;893:1–12
31. Pitt D, Werner P, Raine CS. **Glutamate excitotoxicity in a model of multiple sclerosis [see comments].** *Nat Med* 2000;6:67–70
32. Siegel GJ, Agranoff BW, Albers RW, Molinoff PB, eds. *Basic Neurochemistry: Molecular, Cellular, and Medical Aspects*. 5th ed. New York: Raven Press; 1994
33. Aramburu J, Rao A, Klee CB. **Calcineurin: from structure to function.** *Curr Top Cell Regul* 2000;36:237–295
34. Kader A, Frazzini VI, Solomon RA, Trifiletti RR. **Nitric oxide production during focal cerebral ischemia in rats.** *Stroke* 1993;24:1709–1716
35. Lipton SA, Singel DJ, Stamler JS. **Nitric oxide in the central nervous system.** *Prog Brain Res* 1994;103:359–364
36. Lipton SA, Yeh M, Dreyer EB. **Update on current models of HIV-related neuronal injury: platelet-activating factor, arachidonic acid and nitric oxide.** *Adv Neuroimmunol* 1994;4:181–188
37. Lipton SA, Singel DJ, Stamler JS. **Neuroprotective and neurodestructive effects of nitric oxide and redox congeners.** *Ann N Y Acad Sci* 1994;738:382–387
38. Bukrinsky MI, Nottet HS, Schmidtmayerova H, et al. **Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease.** *J Exp Med* 1995;181:735–745
39. Bonfoco E, Leist M, Zhivotovsky B, Orrenius S, Lipton SA, Nicotera P. **Cytoskeletal breakdown and apoptosis elicited by NO donors in cerebellar granule cells require NMDA receptor activation.** *J Neurochem* 1996;67:2484–2493
40. Christopherson KS, Bredt DS. **Nitric oxide in excitable tissues: physiological roles and disease.** *J Clin Invest* 1997;100:2424–2429
41. Heales SJ, Barker JE, Stewart VC, et al. **Nitric oxide, energy metabolism and neurological disease.** *Biochem Soc Trans* 1997;25:939–943
42. Nicotera P, Brune B, Bagetta G. **Nitric oxide: inducer or suppressor of apoptosis?** *Trends Pharmacol Sci* 1997;18:189–190
43. Yun H-Y, Dawson VL, Dawson TM. **Nitric oxide in health and disease of the nervous system.** *Mol Psychiatry* 1997;2:300–310
44. Dawson VL, Dawson TM. **Nitric oxide in neurodegeneration.** *Prog Brain Res* 1998;118:215–229
45. Lipton SA, Choi YB, Sucher NJ, Chen HS. **Neuroprotective versus neurodestructive effects of NO-related species.** *Biofactors* 1998;8:33–40
46. Luth HJ, Arendt T. **Nitric oxide and Alzheimer’s disease.** *J Hirnforsch* 1998;39:245–251
47. Bredt DS. **Endogenous nitric oxide synthesis: biological functions and pathophysiology.** *Free Radic Res* 1999;31:577–596
48. Callsen-Cencic P, Hoheisel U, Kaske A, Mense S, Tenschert S. **The controversy about spinal neuronal nitric oxide synthase: under which conditions is it up- or downregulated?** *Cell Tissue Res* 1999;295:183–194
49. Heales SJ, Bolanos JP, Stewart VC, Brookes PS, Land JM, Clark JB. **Nitric oxide, mitochondria and neurological disease.** *Biochim Biophys Acta* 1999;1410:215–228
50. Kim WK, Choi YB, Rayudu PV, et al. **Attenuation of NMDA receptor activity and neurotoxicity by nitroxyl anion, NO.** *Neuron* 1999;24:461–469
51. Lipton SA. **Neuronal protection and destruction by NO.** *Cell Death Differentiat* 1999;6:943–951
52. Torreilles F, Salman-Tabcheh S, Guerin M, Torreilles J. **Neurodegenerative disorders: the role of peroxynitrite.** *Brain Res Brain Res Rev* 1999;30:153–163
53. Meng SZ, Ohyu J, Itoh M, Takashima S. **Dopamine transporter and nitric oxide synthase in hypoxic-ischemic brain.** *Pediatr Neurol* 2000;22:115–121
54. Zhang Y, Dawson VL, Dawson TM. **Oxidative stress and genetics in the pathogenesis of Parkinson’s disease.** *Neurobiol Dis* 2000;7:240–250
55. Choi D. **Antagonizing excitotoxicity: a therapeutic strategy for stroke?** *Mount Sinai J Med* 1998;65:133–138
56. Chalmers-Redman RM, Fraser AD, Ju WY, Wadia J, Tatton NA, Tatton WG. **Mechanisms of nerve cell death: apoptosis or necrosis after cerebral ischaemia.** *Int Rev Neurobiol* 1997;40:1–25

57. Aspey BS, Alp MS, Patel Y, Harrison MJ. **Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischemia: an initial screening study.** *Metab Brain Dis* 1997;12:237–249
58. Fujisawa H, Dawson D, Browne SE, MacKay KB, Bullock R, McCulloch J. **Pharmacological modification of glutamate neurotoxicity in vivo.** *Brain Res* 1993;629:73–78
59. Hirose K, Chan PH. **Blockade of glutamate excitotoxicity and its clinical applications.** *Neurochem Res* 1993;18:479–483
60. Redmond JM, Gillinov AM, Blue ME, et al. **The monosialoganglioside, GM1, reduces neurologic injury associated with hypothermic circulatory arrest.** *Surgery* 1993;114:324–332, 332–333
61. Kader A, Frazzini VI, Baker CJ, Solomon RA, Trifiletti RR. **Effect of mild hypothermia on nitric oxide synthesis during focal cerebral ischemia.** *Neurosurgery* 1994;35:272–277
62. Wityk RJ, Stern BJ. **Ischemic stroke: today and tomorrow [see comments].** *Crit Care Med* 1994;22:1278–1293
63. Marini AM, Spiga G, Mocchetti I. **Toward the development of strategies to prevent ischemic neuronal injury: in vitro studies.** *Ann N Y Acad Sci* 1997;825:209–219
64. Chen HS, Wang YF, Rayudu PV, et al. **Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.** *Neuroscience* 1998; 86:1121–1132
65. Qin Z. **A review of therapeutic potentials in ischemic stroke.** *Eur Neurol* 1998;39(Suppl 1):21–25
66. Popovic R, Liniger R, Bickler PE. **Anesthetics and mild hypothermia similarly prevent hippocampal neuron death in an in vitro model of cerebral ischemia.** *Anesthesiology* 2000;92: 1343–1349
67. Ankarcrona M, Dypbukt JM, Bonfoco E, et al. **Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function.** *Neuron* 1995;15: 961–973
68. Budd SL, Nicholls DG. **Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells.** *J Neurochem* 1996;67:2282–2291
69. Kristal BS, Dubinsky JM. **Mitochondrial permeability transition in the central nervous system: induction by calcium cycling-dependent and -independent pathways.** *J Neurochem* 1997;69:524–538
70. Budd SL, Nicholls DG. **Mitochondria in the life and death of neurons.** *Essays Biochem* 1998;33:43–52
71. Castilho RE, Hansson O, Ward MW, Budd SL, Nicholls DG. **Mitochondrial control of acute glutamate excitotoxicity in cultured cerebellar granule cells.** *J Neurosci* 1998;18: 10277–10286
72. Montal M. **Mitochondria, glutamate neurotoxicity and the death cascade.** *Biochim Biophys Acta* 1998;1366:113–126
73. Tatton WG, Chalmers-Redman RM. **Mitochondria in neurodegenerative apoptosis: an opportunity for therapy?** *Ann Neurol* 1998;44(Suppl 1):S134–S141
74. Castilho RE, Ward MW, Nicholls DG. **Oxidative stress, mitochondrial function, and acute glutamate excitotoxicity in cultured cerebellar granule cells.** *J Neurochem* 1999;72: 1394–1401
75. Dubinsky JM, Brustovetsky N, Pinelis V, Kristal BS, Herman C, Li X. **The mitochondrial permeability transition: the brain's point of view.** *Biochem Soc Symp* 1999;66:75–84
76. Greenamyre JT, MacKenzie G, Peng TI, Stephens SE. **Mitochondrial dysfunction in Parkinson's disease.** *Biochem Soc Symp* 1999;66:85–97
77. Grunewald T, Beal MF. **Bioenergetics in Huntington's disease.** *Ann N Y Acad Sci* 1999;893:203–213
78. Nicholls DG, Ward MW. **Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts.** *Trends Neurosci* 2000;23:166–174
79. Nicholls DG, Budd SL. **Mitochondria and neuronal survival.** *Physiol Rev* 2000;80:315–360
80. Dubinsky JM. **Mitochondrial permeability transition (mPT) involvement in the neuronal excitotoxic pathway.** In: Mark LP, ed. 2001
81. Kristian T, Siesjö BK. **Calcium in ischemic cell death.** *Stroke* 1998;29:705–718
82. Gagliardi RJ. **Neuroprotection, excitotoxicity and NMDA antagonists.** *Arq Neuropsiquiatr* 2000;58:583–588
83. Stieg PE, Sathi S, Warach S, Le DA, Lipton SA. **Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat.** *Eur J Pharmacol* 1999;375:115–120
84. Suehiro E, Fujisawa H, Ito H, Ishikawa T, Maekawa T. **Brain temperature modifies glutamate neurotoxicity in vivo.** *J Neurotrauma* 1999;16:285–297
85. Tassorelli C, Joseph SA, Buzzi MG, Nappi G. **The effects on the central nervous system of nitroglycerin: putative mechanisms and mediators.** *Prog Neurobiol* 1999;57:607–624
86. Zaulyanov LL, Green PS, Simpkins JW. **Glutamate receptor requirement for neuronal death from anoxia-reoxygenation: an in vitro model for assessment of the neuroprotective effects of estrogens.** *Cell Mol Neurobiol* 1999;19:705–718
87. Adam-Vizi V. **Neuroprotective effect of sodium channel blockers in ischemia: the pathomechanism of early ischemic dysfunction.** *Orv Hetil* 2000;141:1279–1286
88. Anttila V, Rimpilainen J, Pokela M, et al. **Lamotrigine improves cerebral outcome after hypothermic circulatory arrest: a study in a chronic porcine model.** *J Thorac Cardiovasc Surg* 2000;120:247–255
89. Sastry PS, Rao KS. **Apoptosis and the nervous system.** *J Neurochem* 2000;74:1–20
90. Honig LS, Rosenberg RN. **Apoptosis and neurologic disease.** *Am J Med* 2000;108:317–330
91. Banasiaka KJ, Xiab Y, Haddadbc GG. **Mechanisms underlying hypoxia-induced neuronal apoptosis.** *Prog Neurobiol* 2000;62: 215–249
92. Budd SL, Tenneti L, Lishnak T, Lipton SA. **Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons.** *Proc Nat Acad Sci U S A* 2000;97:6161–6166
93. Roy M, Sapolsky R. **Neuronal apoptosis in acute necrotic insults: why is this subject such a mess?** *Trends Neurosci* 1999; 22:419–422
94. Snider BJ, Gotttron FJ, Choi DW. **Apoptosis and necrosis in cerebrovascular disease.** *Ann N Y Acad Sci* 1999;893:243–253
95. Michel PP, Lambeng N, Ruberg M. **Neuropharmacologic aspects of apoptosis: significance for neurodegenerative diseases.** *Clin Neuropharmacol* 1999;22:137–150
96. Satoh T, Enokido Y, Kubo T, Yamada M, Hatanaka H. **Oxygen toxicity induces apoptosis in neuronal cells.** *Cell Mol Neurobiol* 1998;18:649–666
97. Savitz SI, Rosenbaum DM. **Apoptosis in neurological disease.** *Neurosurgery* 1998;42:555–572, 573–574
98. Leist M, Nicotera P. **Apoptosis versus necrosis: the shape of neuronal cell death.** *Results Probl Cell Differ* 1998;24:105–135
99. Leist M, Nicotera P. **Apoptosis, excitotoxicity, and neuropathology.** *Exp Cell Res* 1998;239:183–201
100. Martin LJ, Al-Abdulla NA, Brambrink AM, Kirsch JR, Sieber FE, Portera-Cailliau C. **Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis.** *Brain Res Bull* 1998;46:281–309
101. Friedlander RM, Yuan J. **ICE, neuronal apoptosis and neurodegeneration [see comments].** *Cell Death Differen* 1998;5: 823–831
102. Gorman AM, Orrenius S, Ceccatelli S. **Apoptosis in neuronal cells: role of caspases.** *Neuroreport* 1998;9:R49–R55
103. Green DR. **Apoptotic pathways: the roads to ruin.** *Cell* 1998; 94:695–698
104. Ankarcrona M. **Glutamate induced cell death: apoptosis or necrosis?** *Prog Brain Res* 1998;116:265–272
105. Casaccia-Bonnel P, Kong H, Chao MV. **Neurotrophins: the biological paradox of survival factors eliciting apoptosis [see comments].** *Cell Death Differen* 1998;5:357–364
106. Johnson EJ, Greenlund LJ, Akins PT, Hsu CY. **Neuronal apoptosis: current understanding of molecular mechanisms and potential role in ischemic brain injury.** *J Neurotrauma* 1995; 12:843–852
107. Prost RW, Mark LP, Mewissen M, Li SJ. **Detection of glutamate/glutamine resonances by ¹H magnetic resonance spectroscopy at 0.5 tesla.** *Magn Reson Med* 1997;37:615–618
108. Sutula T, Koch J, Golarai G, Watanabe Y, McNamara JO. **NMDA receptor dependence of kindling and mossy fiber sprouting: evidence that the NMDA receptor regulates patterning of hippocampal circuits in the adult brain.** *J Neurosci* 1996;16: 7398–7406
109. Sutula T, Zhang P, Lynch M, Sayin U, Golarai G, Rod R. **Synaptic and axonal remodeling of mossy fibers in the hilus and**

- supragranular region of the dentate gyrus in kainate-treated rats.** *J Comp Neurol* 1998;390:578–594
110. Sutula TP. **Experimental models of temporal lobe epilepsy: new insights from the study of kindling and synaptic reorganization.** *Epilepsia* 1990;31(Suppl 3):S45–S54
 111. Sutula TP. **Reactive changes in epilepsy: cell death and axon sprouting induced by kindling.** *Epilepsy Res* 1991;10:62–70
 112. McNamara JO. **Kindling: an animal model of complex partial epilepsy.** *Ann Neurol* 1984;16(Suppl):S72–S76
 113. McNamara JO. **Role of neurotransmitters in seizure mechanisms in the kindling model of epilepsy.** *Fed Proc* 1984;43:2516–2520
 114. McNamara JO. **Kindling model of epilepsy.** *Adv Neurol* 1986;44:303–318
 115. McNamara JO. **Development of new pharmacological agents for epilepsy: lessons from the kindling model.** *Epilepsia* 1989;30(Suppl 1):S13–S18, S64–S68
 116. McNamara JO. **Excitatory amino acid receptors and epilepsy.** *Curr Opin Neurol Neurosurg* 1993;6:583–587
 117. McNamara JO. **Identification of genetic defect of an epilepsy: strategies for therapeutic advances.** *Epilepsia* 1994;35(Suppl 1):S51–S57
 118. McNamara JO. **Emerging insights into the genesis of epilepsy.** *Nature* 1999;399(Suppl):A15–A22
 119. McNamara JO, Yeh G, Bonhaus DW, Okazaki M, Nadler JV. **NMDA receptor plasticity in the kindling model.** *Adv Exp Med* 1990;268:451–459
 120. Sherwin A, Robitaille Y, Quesney F, et al. **Excitatory amino acids are elevated in human epileptic cerebral cortex.** *Neurology* 1988;38:920–923
 121. Hamberger A, Nystrom B, Larsson S, Silfvenius H, Nordborg C. **Amino acids in the neuronal microenvironment of focal human epileptic lesions.** *Epilepsy Res* 1991;9:32–43
 122. Mark LP, Prost R, Yetkin Z, Haughton VM. **An MR Spectroscopic Study of Glutamate in Patients with Temporal Lobe Seizures.** Presented at the 33rd annual meeting of the American Society of Neuroradiology, Chicago, 1995
 123. Reynolds NC, Prost RW, Mark LP. **Evidence for Excitotoxicity: Comparisons of Proton Magnetic Resonance Spectroscopy in Huntington's Disease, Idiopathic Dystonia and Progressive Supranuclear Palsy.** Presented at the 5th International Congress of Parkinson's Disease and Movement Disorders, New York, 1998
 124. Reynolds NC, Prost RW, Mark LP. **Monitoring Neuroprotective Treatment of Patients at Risk for Huntington's Disease Using Magnetic Resonance Spectroscopy at 0.5 Tesla.** Presented at the 28th annual meeting of the Society for Neuroscience, Los Angeles, 1998
 125. Reynolds NC, Prost RW, Mark LP. **Proton Magnetic Resonance Spectroscopy in Huntington's Disease: Indicators of Early Pathophysiologic Changes.** Presented at the 6th International Congress of Parkinson's Disease and Movement Disorders, Barcelona, 2000